Table 1 Changes in patients’ underlying characteristics between 2007 and 2018
Characteristics | 2007–2008 | 2009–2010 | 2011–2012 | 2013–2014 | 2015–2016 | 2017–2018 | p |
|---|---|---|---|---|---|---|---|
(n = 181) | (n = 230) | (n = 241) | (n = 263) | (n = 291) | (n = 319) | ||
Proportions of concurrent ICU admissions (%) | 6.1 | 7.5 | 7.4 | 7.2 | 8.4 | 10.2 | < 0.001 |
Age (years) | 70 [59–78] | 68 [59–76] | 67 [60–75] | 66 [57–75] | 67 [59–74] | 67 [60–74] | 0.15 |
Male gender | 126 (69.6) | 143 (62.2) | 152 (63.1) | 159 (60.5) | 163 (56) | 201 (63) | 0.87 |
Non-cancer comorbid conditions | |||||||
Hypertension | 76 (42.0) | 97 (42.2) | 97 (40.2) | 120 (45.6) | 131 (45.0) | 138 (43.3) | 0.45 |
Diabetes | 38 (21.0) | 44 (19.1) | 31 (12.9) | 60 (22.8) | 55 (18.9) | 61 (19.1) | 0.88 |
Cirrhosis | 10 (5.5) | 18 (7.8) | 17 (7.1) | 17 (6.5) | 19 (6.5) | 20 (6.3) | 0.85 |
Chronic renal failure | 20 (11.0) | 20 (8.7) | 18 (7.5) | 29 (11.0) | 28 (9.6) | 22 (6.9) | 0.34 |
Chronic heart failure | 8 (4.4) | 14 (6.1) | 9 (3.7) | 23 (8.7) | 11 (3.8) | 16 (5.0) | 0.93 |
Type of cancer | < 0.001 | ||||||
Lung | 50 (27.6) | 55 (24.1) | 50 (20.7) | 60 (22.8) | 69 (23.7) | 95 (29.8) | |
Gastrointestinal | 25 (13.8) | 44 (19.1) | 72 (29.9) | 90 (34.2) | 86 (29.5) | 80 (25.1) | |
Urologic | 51 (28.2) | 63 (27.4) | 48 (19.9) | 47 (17.9) | 47 (16.2) | 58 (18.2) | |
Breast | 16 (8.8) | 29 (12.7) | 22 (9.1) | 24 (9.1) | 34 (11.7) | 28 (8.8) | |
Head and neck | 12 (6.6) | 11 (4.8) | 12 (5.0) | 5 (1.9) | 7 (2.4) | 7 (2.2) | |
Gynaecologic | 10 (5.5) | 8 (3.5) | 13 (5.4) | 9 (3.4) | 10 (3.4) | 13 (4.1) | |
Skin | 1 (0.6) | 3 (1.3) | 2 (0.8) | 3 (1.1) | 10 (3.4) | 7 (2.2) | |
Others | 16 (8.9) | 17 (7.4) | 22 (9.1) | 25 (9.5) | 28 (9.6) | 31 (9.7) | |
Time from diagnosis to ICU admission (days) | 259 [43–722] | 237 [43–833] | 254 [61–967] | 291 [99–1024] | 267 [57–914] | 264 [70–736] | 0.23 |
Stage a | 0.004 | ||||||
Localized | 53 (29.3) | 66 (28.7) | 65 (27.0) | 58 (22.1) | 70 (24.1) | 60 (18.8) | |
Advanced | 34 (18.8) | 55 (23.9) | 50 (20.7) | 46 (17.5) | 62 (21.3) | 67 (21.0) | |
Metastatic | 88 (48.6) | 106 (46.1) | 125 (51.9) | 157 (59.7) | 156 (53.6) | 192 (60.2) | |
Current cancer status | < 0.001 | ||||||
Newly diagnosed | 62 (34.3) | 72 (31.3) | 71 (29.5) | 58 (22.1) | 96 (33.0) | 82 (25.7) | |
Partial remission | 19 (10.5) | 26 (11.3) | 47 (19.5) | 70 (26.6) | 55 (18.9) | 83 (26.0) | |
Complete remission | 26 (14.4) | 48 (20.9) | 37 (15.4) | 37 (14.1) | 36 (12.4) | 36 (11.3) | |
Progressive | 65 (35.9) | 80 (34.8) | 85 (35.3) | 94 (35.7) | 102 (35.1) | 114 (35.7) | |
Recent oncological treatment (< 3 months) | |||||||
Antitumoral drug treatment | 69 (38.5) | 98 (42.8) | 115 (47.7) | 141 (53.6) | 163 (56.0) | 170 (53.3) | 0.001 |
Immunotherapy and targeted therapy | 8 (4.4) | 18 (7.8) | 17 (7.1) | 35 (13.3) | 37 (12.7) | 60 (18.8) | < 0.001 |
First-line treatment | 45 (25.0) | 58 (25.2) | 63 (26.1) | 4 (28.1) | 91 (31.3) | 83 (26.0) | 0.577 |
Radiotherapy | 13 (7.2) | 17 (7.4) | 16 (6.7) | 22 (8.4) | 17 (5.8) | 22 (6.9) | 0.543 |
Surgery | 30 (16.8) | 38 (16.5) | 35 (14.5) | 37 (14.1) | 25 (8.6) | 47 (14.7) | 0.184 |